Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease

Симвастатин и ниацин, антиоксидантные витамины или их комбинация для профилактики коронарной болезни
Alan Chait, John J. Albers, Petar Alaupovic, Jiří Fröhlich, Bryan Brown, Xue-Qiao Zhao, Lloyd D. Fisher, Marian C. Cheung, Josh S. Morse, Alice Dowdy, Emily K Marino, Edward L. Bolson, Petar Alaupovic, Leny Serafini, Ellen Huss-Frechette, Shari Wang, Debbie DeAngelis, Arthur Dodek
2001-11-29

antioxidant vitaminscoronary diseasecoronary stenosislow HDL cholesterolsimvastatin-niacin therapy
BACKGROUND: Both lipid-modifying therapy and antioxidant vitamins are thought to have benefit in patients with coronary disease. We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary disease and low plasma levels of HDL. METHODS: In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos. The end points were arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization). RESULTS: The mean levels of LDL and HDL cholesterol were unaltered in the antioxidant group and the placebo group; these levels changed substantially (by -42 percent and +26 percent, respectively) in the simvastatin-niacin group. The protective increase in HDL2 with simvastatin plus niacin was attenuated by concurrent therapy with antioxidants. The average stenosis progressed by 3.9 percent with placebos, 1.8 percent with antioxidants (P=0.16 for the comparison with the placebo group), and 0.7 percent with simvastatin-niacin plus antioxidants (P=0.004) and regressed by 0.4 percent with simvastatin-niacin alone (P<0.001). The frequency of the clinical end point was 24 percent with placebos; 3 percent with simvastatin-niacin alone; 21 percent in the antioxidant-therapy group; and 14 percent in the simvastatin-niacin-plus-antioxidants group. CONCLUSIONS: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned.
1
Antioxidants attenuated the simvastatin–niacin-associated increase in HDL2, questioning their use alongside lipid-modifying therapy in this setting.
2
Coronary stenosis regressed by 0.4% with simvastatin–niacin alone, compared with 3.9% progression with placebo (P<0.001).
3
First cardiovascular events occurred in 3% of patients receiving simvastatin–niacin, versus 24% with placebo and 21% with antioxidants alone.
4
In a three-year randomized trial of 160 patients, simvastatin plus niacin substantially reduced LDL cholesterol by 42% and increased HDL cholesterol by 26%.
5
Simvastatin–niacin plus antioxidants limited stenosis progression to 0.7%, but was less effective than simvastatin–niacin alone.

Patients with coronary disease, low HDL cholesterol, and normal LDL cholesterol receiving simvastatin–niacin and/or antioxidant-vitamin therapy

Effects of simvastatin–niacin and antioxidant vitamins, alone or combined, on coronary stenosis progression, lipid levels, and cardiovascular events

Publication Details
Publication Date
2001-11-29
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Alan Chait
John J. Albers
Petar Alaupovic
Jiří Fröhlich
Bryan Brown
Xue-Qiao Zhao
Lloyd D. Fisher
Marian C. Cheung
Josh S. Morse
Alice Dowdy
Emily K Marino
Edward L. Bolson
Petar Alaupovic
Leny Serafini
Ellen Huss-Frechette
Shari Wang
Debbie DeAngelis
Arthur Dodek
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%